CVS Health Corp. (NYSE:CVS)

The period under review demonstrates fluctuating financial performance as measured by economic profit. Net operating profit after taxes (NOPAT) exhibited volatility, beginning at US$9,067 million in 2020, increasing to US$9,170 million in 2021, then declining significantly to US$3,871 million in 2022, before recovering to US$9,523 million in 2023 and subsequently decreasing to US$5,319 million in 2024.

The cost of capital experienced an upward trend from 2020 to 2022, rising from 7.62% to 8.96%, followed by a decrease to 8.34% in 2023 and a further reduction to 8.01% in 2024. Invested capital generally decreased from 2020 to 2022, falling from US$136,669 million to US$123,703 million, before increasing to US$134,694 million in 2023 and decreasing slightly to US$131,642 million in 2024.

Economic Profit Trend

Economic profit consistently remained negative throughout the observed period. The largest negative economic profit occurred in 2022, reaching US$-7,210 million. While the negative economic profit lessened in 2023 to US$-1,704 million, it increased again in 2024 to US$-5,225 million. This indicates that, despite positive NOPAT in some years, the returns generated were insufficient to cover the cost of capital employed.

Relationship between NOPAT and Economic Profit

The decline in NOPAT in 2022 directly contributed to the most substantial negative economic profit for that year. The recovery of NOPAT in 2023 resulted in a reduced negative economic profit, but the subsequent decrease in NOPAT in 2024 led to a worsening of the economic profit position.

Impact of Cost of Capital

The increasing cost of capital from 2020 to 2022 exacerbated the negative economic profit, as a higher cost of capital further reduced the returns available to investors. The subsequent decrease in the cost of capital in 2023 and 2024 partially offset the negative impact, but was not sufficient to generate positive economic profit.

Overall, the analysis suggests a consistent failure to generate returns exceeding the cost of capital during the period. Fluctuations in NOPAT, coupled with changes in the cost of capital, significantly influenced the magnitude of the economic loss.

Net income attributable to CVS Health

The net income exhibited fluctuations over the five-year period. Starting at $7,179 million in 2020, there was an increase to $7,910 million in 2021, indicating growth. However, in 2022, net income notably declined to $4,149 million, reflecting a significant drop. This was followed by a rebound in 2023, reaching $8,344 million, which represents the highest point in the period. In 2024, net income once again decreased to $4,614 million, showing volatility and an overall irregular pattern in earnings.

Net operating profit after taxes (NOPAT)

NOPAT followed a pattern broadly similar to net income but with less pronounced volatility. It began at $9,067 million in 2020 and slightly increased to $9,170 million in 2021. In 2022, there was a sharp decline to $3,871 million, mirroring the net income decline of that year. The subsequent year, 2023, saw a recovery to $9,523 million, the highest level observed in this timeframe. By 2024, NOPAT decreased again to $5,319 million. This trend suggests that while operating profitability is subject to cyclical pressures, it remains relatively strong when it rebounds.

Insights

The data reveals substantial volatility in both net income and NOPAT with synchronous fluctuations particularly pronounced in 2022 and 2024. These troughs could indicate periods of operational or market challenges impacting profitability. Despite these downturns, the company demonstrated resilience with robust recoveries in 2023, suggesting effective management responses or favorable market conditions during that year. The gap between net income and NOPAT levels also suggests that non-operating factors or tax impacts may play a role in overall profitability fluctuations. The irregular pattern underscores the importance of closely monitoring operational efficiency and external factors influencing financial performance.

Income Tax Provision

The income tax provision exhibited a fluctuating trend over the years observed. It decreased from $2,569 million in 2020 to $2,522 million in 2021, indicating a slight reduction. This was followed by a more significant decline to $1,463 million in 2022. However, in 2023, the provision increased sharply to $2,805 million, before decreasing again to $1,562 million in 2024. Overall, the income tax provision shows variability with notable peaks and troughs during the five-year period.

Cash Operating Taxes

Cash operating taxes showed a moderate decline from $3,769 million in 2020 to $3,407 million in 2021. In 2022, there was an increase to $4,013 million, marking the highest point in the period reviewed. Subsequently, the amount slightly decreased to $3,965 million in 2023, followed by a significant drop to $2,464 million in 2024. This pattern indicates some volatility with an overall downward movement towards the end of the period.

Comparative Insights

Both income tax provision and cash operating taxes demonstrate considerable year-to-year fluctuations. Cash operating taxes consistently remained higher than the income tax provision across all years. The disparity between the two measures also varied, with the smallest gap occurring in 2024. This suggests possible changes in tax planning, timing differences, or cash tax payments relative to accounting tax expense over the evaluated periods.

Total reported debt & leases

The total reported debt and leases decreased from 85,042 million US dollars at the end of 2020 to 70,732 million US dollars by the end of 2022. This decline indicates a reduction in leverage during this period. However, starting from 2023, there is a notable increase, rising to 79,385 million US dollars and further to 82,920 million US dollars by the end of 2024, suggesting renewed borrowing or leasing commitments.

Total CVS Health shareholders’ equity

Shareholders’ equity showed a rising trend from 69,389 million US dollars in 2020, peaking at 75,075 million in 2021. Following this peak, equity experienced a slight pullback to 71,015 million in 2022 but recovered to 76,461 million in 2023. By 2024, it marginally declined again to 75,560 million US dollars. Overall, equity levels remained relatively stable with moderate fluctuations around the mid-70 billion range in the most recent years.

Invested capital

Invested capital declined steadily from 136,669 million US dollars in 2020 to 123,703 million in 2022, reflecting overall reductions in capital employed. This trend reversed in 2023 with an increase to 134,694 million followed by a slight decrease to 131,642 million in 2024. The pattern suggests a cycle of divestments or asset optimization up to 2022 and subsequent reinvestment or capital expansion over the following years, indicating adjustments in capital structure or operational focus.

The economic spread ratio exhibited considerable fluctuation between 2020 and 2024. Initially negative, the ratio demonstrated a worsening trend before showing some improvement, though remaining negative throughout the period. Economic profit consistently registered as a negative value, indicating the company’s returns did not exceed its cost of capital during these years.

Economic Spread Ratio

In 2020, the economic spread ratio was -0.99%. This value deteriorated significantly to -5.83% in 2022, representing the most substantial negative spread observed during the analyzed timeframe. A subsequent improvement was noted in 2023, with the ratio increasing to -1.27%. This positive shift, however, was not sustained, as the ratio decreased again to -3.97% in 2024. The overall trend suggests a struggle to generate returns exceeding the cost of capital, with 2022 being the most challenging year.

Economic Profit

Economic profit moved from -1,353 million in 2020 to -2,381 million in 2021, indicating an increase in the absolute value of the loss. The largest negative economic profit was recorded in 2022 at -7,210 million. A substantial improvement occurred in 2023, with economic profit lessening to -1,704 million. However, this improvement was partially reversed in 2024, with economic profit reported as -5,225 million. The pattern mirrors the economic spread ratio, suggesting a correlation between the two metrics.

Invested Capital

Invested capital decreased from 136,669 million in 2020 to 123,703 million in 2022. A rebound was observed in 2023, with invested capital rising to 134,694 million. The level then decreased slightly to 131,642 million in 2024. While fluctuations occurred, the invested capital remained relatively stable overall, suggesting changes in economic profit and spread were not primarily driven by significant shifts in capital employed.

The combined analysis of these metrics indicates a period of underperformance relative to the cost of capital. While some improvement was seen in 2023, the company did not achieve positive economic profit or a positive economic spread ratio during the examined period. The substantial decline in the economic spread ratio in 2022 warrants further investigation to understand the underlying drivers of this performance.

The economic profit margin exhibited considerable fluctuation between 2020 and 2024. Initially negative, the margin worsened significantly over the period before showing some improvement, though remaining negative overall. A detailed examination of the trends is presented below.

Economic Profit Margin Trend

In 2020, the economic profit margin stood at -0.51%. This metric then deteriorated to -0.82% in 2021, indicating a widening gap between the company’s cost of capital and the returns generated from its revenues. The most substantial decline occurred in 2022, with the margin reaching -2.24%, representing a significant underperformance in economic profit generation relative to revenue. A notable improvement was observed in 2023, with the margin increasing to -0.48%, suggesting a partial recovery in economic profitability. However, this positive trend was not sustained, as the margin decreased again in 2024 to -1.41%.

The economic profit margin’s movement closely mirrors the trend in economic profit. The largest absolute value of economic profit occurred in 2022, coinciding with the lowest economic profit margin. While revenues consistently increased year-over-year, the economic profit margin indicates that these revenue gains were insufficient to offset the cost of capital and generate positive economic profit. The 2023 improvement in margin, despite a continued negative value, suggests some efficiency gains or a reduction in the cost of capital relative to the prior year. However, the subsequent decline in 2024 indicates these improvements were not maintained.

Revenue Growth vs. Margin Performance

Revenues from customers increased steadily from US$267,908 million in 2020 to US$370,656 million in 2024. Despite this consistent revenue growth, the economic profit margin remained negative throughout the period, and experienced substantial volatility. This suggests that while the company is successfully increasing sales, it is struggling to translate those sales into economic profit. The widening margin decline in 2022, despite revenue increases, is particularly noteworthy.

The observed pattern suggests a potential disconnect between revenue generation and the company’s ability to generate returns exceeding its cost of capital. Further investigation into the factors driving the cost of capital and the efficiency of revenue generation would be warranted.